OncoNano Medicine, Inc. today announced that it has been awarded $15.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates. In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV). This grant award adds to an initial $6 million grant that the company received from CPRIT in 2014 for advancement of the company’s ONM-100, where OncoNano’s micelle technology is being used to intraoperatively image tumors during surgical resection, currently in Phase 2 clinical trials... (read more)

OncoNano Medicine, Inc. today announced the completion of its Phase 1a clinical trial and expansion into Phase 1b to evaluate ONM-100, the intravenously administered imaging agent to detect tumors and metastatic lymph nodes in solid cancers during surgery. The results of Phase 1a will be included in a poster presentation at the San Antonio Breast Cancer Symposium being held on December 4-8, 2018... (read more)

​AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In concert with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow, MBA... (read more)

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018... (read more)

Synteract has snapped up the specialty contract researcher Cu-Tech, with plans to establish a dedicated center for the development of dermatology products and make the midsized, global CRO into a destination for skin-care clinical trials.
​
The Mountain Lakes, New Jersey-based Cu-Tech has managed more than 130 dermatology trials over the past two decades, covering a variety of indications... (read more)

SOUTHLAKE, TX - OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to support the company’s continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer. The company is also pleased to announce the appointment of five established industry leaders to its Board of Directors... (read more)

LOS ANGELES, CA - Salem Partners is pleased to announce the successful completion of a large programmatic joint-venture in the real estate / medical office sector for its client, Everest Medical Core Properties (“Everest MCP”). The joint-venture is between Everest MCP and a major, U.S. based real estate private equity firm.... (read more).

ATLANTA, GA - December 14, 2015 --- Femasys Inc., a developer of innovative medical devices for the women’s healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys’ principal financial and... (read more)

LONDON — The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash.  The transaction is expected to improve AstraZeneca’s pipeline of treatments for cardiovascular and metabolic diseases and comes as the British drug maker is set to lose exclusivity in the United States for its best-selling cholesterol treatment, Crestor...(read more)

Dallas/Fort Worth, TX (July 23, 2015) — Neos Therapeutics, Inc. (“Neos” or “the Company”) today announced the pricing of its initial public offering of 4,800,000 shares of common stock at an initial public offering price of $15.00 per share. In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock at the initial public offering... (read more)

ATLANTA, July 9, 2015 /PRNewswire/ -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, announced today that it has secured a term loan facility from Silicon Valley Bank.  Under the loan facility, the company ... (read more)

After bringing in one of the top venture capital investments during first quarter 2015, Neos Therapeutics has filed for an initial public offering.  The Grand Prairie-based company, which develops medication for Attention Deficit/Hyperactivity Disorder, filed Friday to trade on the Nasdaq under ticker symbol NEOS. It has a place holder value... (read more)

LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., the pioneer in LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine strategies, announced today the completion... (read more)

REDWOOD CITY, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it has submitted a New Drug Application (NDA) to... (read more)

Atlanta, GA -April 29, 2015 - Femasys Inc., a developer of innovative medical devices for the women's healthcare market has raised a $10.2 million financing round. The investor group was led by Legacy Capital Partners and Mario Family Partners, the family offices of... (read more)

COPPELL, Texas, July 8, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark...(read more) 

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in...(read more)

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the pricing of its initial public offering of 5,944,444 shares of its common stock at a price to the public of $18.00 per share. The shares are expected to begin... (read more)

In corporate development there are few investable and actionable certainties. Here today, in 2014, we face one of the most significant certainties that operators and investors will encounter for decades to come – the comprehensive redesign of the health services and life sciences industries.

In this healthcare & life sciences report, we highlight today’s growth areas and opportunities, with an aim to provide insight into current trends and business drivers. This report explores the shifts taking place within the US healthcare industry to enable stakeholders to formulate better decisions and strategies. Our overarching goal is to ensure that providers, investors and corporate development professionals remain well-placed to realize healthy returns. (read more)

DALLAS/FORT WORTH, Texas, Apr 23, 2014 (BUSINESS WIRE) -- Neos Therapeutics, Inc. (“Neos” or “the Company”),a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has entered into a $20 million loan facility with Hercules... (read more)

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. The investor syndicate was led by Novo A/S and included new investors RA Capital, Adage Capital, Sofinnova Ventures, and... (read more)

DALLAS/FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total... (read more)

October 23, 2012 - Specialty pharmaceutical company ZS Pharma, Inc. has raised $46 million to advance development of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.  Alta Partners led the new round of financing, joined by new investors RiverVest Venture Partners, 3x5 Special Opportunity Partners and Salem Partners ... (read more)